tbuckley/cabot-search huggingface dataset:
AB1625-HPR ONLINE PATIENT PORTAL FOR PATIENTS WITH AXIAL SPONDYLOARTHRITIS: AN OVERVIEW OF OUR EXPERIENCE
Authors: L. Sammut, M. Brent, V. Hannah, C. Beevor, L. Lowe, C. Jeffries
Journal: Annals of the Rheumatic Diseases (2024)

<h3>Background:</h3> Patient portals are becoming increasing popular worldwide providing access to electronic health records and health related information. It may also provide a digital tool of communicating and sharing information with the patient's clinical team. Patient portals offer the means for patients to better understand their chronic health condition, treatment plans, and decisions, thus supporting self-management and potentially improving healthcare utilisation and efficiency. A multi-disciplinary team developed a web based patient portal tailored for patients diagnosed with axial spondyloarthritis. <h3>Objectives:</h3> This case study presents experiences from the implementation, usability, outcomes and patient satisfaction of this patient portal tailored for patients diagnosed with axial spondyloarthritis. <h3>Methods:</h3> Data was collected on patient registration. The number of logins, messages, virtual reviews, and outcome measures submitted to the rheumatology department via the portal was collected. Patient experience data through surveys via the website itself was also evaluated. <h3>Results:</h3> Following extensive development work and consultations with a patient group, the web-based patient portal was launched on the 5th January 2023. All patients with a background of axial spondyloarthritis were invited to register. 241 patients have registered over a 9 month period with 193 patients visiting the patient portal at least once. 145 patients visited the patients more than once since registration. There was a total of 112 virtual reviews, 27 messaging threads and 554 documents sent via the patient portal. On average there were 6 outcome measures sent per month via the patient portal. In a subset of patients who completed the patient experience survey, 93% (n = 39) of patients found accessing the portal very easy or easy to use. 64.3% (n=27) of patients felt that the portal helped them to take control of their condition. <h3>Conclusion:</h3> Early experience with the patient portal showed strong reports of a positive patient experience and high usability. Patient access to this patient portal can support self-management of axial spondyloarthritis and it has the potential to become a valuable resource for up to date information. The patient portal was also an invaluable tool in facilitating communication between the clinical team and the patient and reduced delays in sending disease activity questionnaires by post. Further data is needed to evaluate whether the use of this patient portal improves health care utilisation and efficiency. <h3>REFERENCES:</h3> <b>NIL.</b> <h3>Acknowledgements:</h3> <b>NIL.</b> <h3>Disclosure of Interests:</h3> <b>None declared.</b>
AB1545-HPR THE FACTORS RELATED TO PHYSICAL PERFORMANCE IN FEMALE PATIENTS WITH PSORIATIC ARTHRITIS
Authors: İ. İnanc, D. Solmaz, D. C. Saraç, E. Başkan, A. Özkan, K. Yucel, S. Akar, D. Bayraktar
Journal: Annals of the Rheumatic Diseases (2024)

<h3>Background:</h3> Psoriatic arthritis (PsA) is characterized by peripheral and/or axial manifestations with prominent features of dactylitis and enthesitis. Having PsA may negatively affect physical performance in daily life. However, best to our knowledge, no study investigated the possible factors related to physical performance in patients with PsA. <h3>Objectives:</h3> To investigate the correlations between physical performance and trunk muscle endurance, spinal mobility, fatigue, self-reported functional status, disease activity, emotional status, and disease-related quality of life in female patients with PsA. <h3>Methods:</h3> Ankylosing Spondylitis Performance Index (ASPI) including three tasks (bending to pick-up 6 pencils from the floor, putting on socks, and getting up from the floor) was used to evaluate physical performance. Trunk muscle endurance was measured by using side bridge test. Spinal mobility was assessed with Bath Ankylosing Spondylitis Metrology Index (BASMI). Fatigue and self-reported functional status were evaluated with Fatigue Severity Scale (FSS) and Bath Ankylosing Spondylitis Functional Index (BASFI), respectively. Disease Activity in Psoriatic Arthritis (DAPSA) scores were calculated to assess disease activity. Hospital Anxiety and Depression Scale (HADS) was employed to evaluate emotional status. Disease-related quality of life was assessed with PsA-specific quality of life questionnaire (PsAQoL). <h3>Results:</h3> Thirty-four female PsA patients with a median age of 49.0 years (IQR 25/75: 38.0/54.0 years) were included in the study. The physical and sociodemographic characteristics of the patients are presented in Table 1. Weak to moderate correlations were detected between all physical performance tasks and trunk muscle endurance, spinal mobility, fatigue, and disease-related quality of life (rho between 0.338 and 0.698, p&lt;0.05, Table 2). Two ASPI tasks (bending to pick up 6 pencils from the floor, getting up from the floor) moderately correlated with self-reported functional status and disease activity (p&lt;0.05, Table 2). No correlation was detected between physical performance and emotional status (p&gt;0.05, Table 2). <h3>Conclusion:</h3> Physical performance seems related to many aspects of PsA such as trunk muscle strength, spinal mobility, fatigue, self-reported functional status, disease activity, and disease-related quality of life. Thus, assessing physical performance on a regular basis can be beneficial to clinicians. Additionally, disease management strategies targeting physical performance may help to improve disease outcomes or vice versa. <h3>REFERENCES:</h3> <b>NIL.</b> <h3>Acknowledgements:</h3> <b>NIL.</b> <h3>Disclosure of Interests:</h3> <b>None declared.</b>
AB1522 COMPARATIVE EFFECTIVENESS OF OSTEOPOROSIS MEDICATIONS ON DISEASE ACTIVITY IN RHEUMATIC MUSCULOSKELETAL DISORDERS
Authors: A. Giollo, A. Cuberli, M. Salvato, F. Frizzera, A. Doria
Journal: Annals of the Rheumatic Diseases (2024)

<h3>Background:</h3> Glucand fragility fractures are common comorbidities in patients with rheumatic and musculoskeletal diseases (RMD) such as rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). Although anti-resorptive and anabolic agents are recommended to reduce fracture risks in GIO, their effects on controlling the underlying disease activity of RMD have received less attention. Previous research suggests that inhibiting RANK with denosumab (DMAB) may have immunosuppressive effects. Teriparatide (TPD) and romosozumab (ROMO) are two drugs about which little is known. <h3>Objectives:</h3> To compare disease activity control across groups of RMD patients with GIO receiving osteoporosis treatment with denosumab, teriparatide, romosozumab, or zoledronic acid (ZA). <h3>Methods:</h3> This prospective cohort study included patients from a specialty osteoporosis clinic with RMDs who began osteoporosis therapy in the years 2021-2022. The primary outcome was disease activity at the next clinical assessment for RMD. To account for differences in several activity measures, disease activity was homogenised on an ordinal 3-point scale (remission, low, moderate/high) at baseline and follow-up according to a independent assessor. The analysis of variance was used to compare disease activity score changes an ross groups over time, while controlling for baseline fracture risk assessment tool (FRAX). <h3>Results:</h3> During the study period, 99 RMD patients were given one of the study medications, and 44 of them had a follow-up evaluation at a median of 6.8 (range 2.7 to 13.6) months and were analysed (DMAB: n = 11, TPD/ROMO: n = 13, and ZA: n = 20). At baseline (Table 1), the majority of patients (55%), had chronic inflammatory arthritis, had taken oral bisphosphonates, had vertebral fractures, and were at high fracture risk. Follow-up disease activity scores decreased by -0.2 points for ZA, -0.5 points for DMAB, and increased by 0.4 points for TPD/ROMO groups (Figure 1), with only the DMAB group showing significant between-group differences in improvement over follow-up (mean difference -0.8, 95% CI -1.6 to -0.02, p=0.043). However, this was not evident in the adjusted analysis, which included baseline FRAX as a covariate. <h3>Conclusion:</h3> In this small sample, there were no statistically significant differences between osteoporosis medications in disease activity improvement among patients with inflammatory rheumatic diseases and GIO. Fracture risk might mediate the effect of osteoporosis medications and disease activity control. Larger pragmatic trials are warranted. <h3>REFERENCES:</h3> <b>NIL.</b> <h3>Acknowledgements:</h3> <b>NIL.</b> <h3>Disclosure of Interests:</h3> <b>None declared.</b>
AB1657-PARE IMPACT OF INTERMITTENT FASTING DURING RAMADAN ON AXIAL SPONDYLOARTHRITIS: PATIENT PERCEPTIONS AND COMPLIANCE
Authors: H. L’heri, T. Latifa, I. Bensaghir, S. Farih, R. Honsali, S. Ez-Zaoui, F. Kronbi, N. Benzine, H. Rkain, F. Allali
Journal: Annals of the Rheumatic Diseases (2024)

<h3>Background:</h3> Ramadan, the ninth month of the lunar calendar, holds great significance as a sacred month for Muslims worldwide. Central to Islamic practice, fasting during Ramadan is a fundamental pillar, mandatory for all adult Muslims, with exceptions based on specific health conditions. It involves abstaining from food and drink daily from dawn to sunset throughout this holy month. <h3>Objectives:</h3> The aim of this study is to explore the beliefs and attitudes of patients with axial spondyloarthritis (SpA) towards Ramadan intermittent fasting (RIF). <h3>Methods:</h3> A descriptive and cross-sectional study was undertaken involving 50 SpA patients. Data was collected through a Google Form questionnaire, which encompassed three sections: sociodemographic details, disease characteristics, and patients attitudes towards fasting. <h3>Results:</h3> The study included 50 patients, with a mean age of 37.1 ± 11.4 years. Seventy percent of the participants were male, and the median duration of SpA was 6.5 [2.6; 10] years. A majority (94%) of the patients were undergoing biological treatment. Among the participants, 78% reported regular consultations with their rheumatologist. Notably, all participants chose to fast despite receiving an axial spondyloarthritis diagnosis. Although 70% expressed a lack of information regarding RIF specific implications for SpA, a significant portion (44%) perceived potential benefits for their rheumatic disease. Concerning the impact of RIF on rheumatism, most participants (58% for pain, 62% for morning stiffness, and 46% for fatigue) reported no noticeable changes in symptoms. Importantly, neither compliance nor therapeutic observance was affected by fasting for all anti-rheumatic treatments provided during this period. <h3>Conclusion:</h3> This study offers a comprehensive overview of the attitudes of SpA patients towards fasting during Ramadan. It underscores the crucial need for comprehensive educational programs that equip patients with the knowledge and skills to manage their medications, monitor their symptoms, and fast safely during this month. <h3>REFERENCES:</h3> <b>NIL.</b> <h3>Acknowledgements:</h3> <b>NIL.</b> <h3>Disclosure of Interests:</h3> <b>None declared.</b>
AB1721 EXPLORING OCCUPATIONAL PARTICIPATION IN CHILDREN WITH JUVENILE IDIOPATHIC ARTHRITIS: A QUALITATIVE STUDY ON PARENTS &amp; CARERS PERSPECTIVES
Authors: A. Wescott
Journal: Annals of the Rheumatic Diseases (2024)

<h3>Background:</h3> Juvenile Idiopathic Arthritis (JIA) is a long-term condition diagnosed before 16 years of age and is the most common rheumatic condition in children. It is reported that children and young people with JIA have reduced health related quality of life and participate less in physical and social activities. Participation within family occupations is vital for a child's development, however little research has been completed into how JIA impacts the child and the family's occupational participation. <h3>Objectives:</h3> To explore parents/caregiver's perspectives of their child and family's occupational participation and how JIA has an impact on this. Barriers and facilitators to participation were also to be investigated. <h3>Methods:</h3> The project was approved by the University of Worcester's ethics committee following submission of the relevant documents. A phenomenological approach was chosen as this encompasses an interpretive constructivist paradigm. This study aims to understand the lived experiences of parents/caregivers of a child with JIA and phenomenology recognises the depth of information that a person's lived experience can offer to research. Using a qualitative methodology, eight semi-structured interviews were conducted to gain the perspectives of parents/caregivers. Data was analysed using Thematic Analyse and themes were identified. <h3>Results:</h3> Three main themes were found with six subthemes. These were "Just getting on with it" including planning and adapting. Outside support including relationships and support groups. Finally, the impact on mental health including the child's mental health and parental stress. JIA has an impact the whole family unit which in turn influences occupational participation. The mental health aspect was significant when exploring the family's occupational participation. <h3>Conclusions:</h3> Occupational therapists and allied health professionals can use the knowledge gained from this study to ensure collaborated approaches with families are taken to address family occupational participation. Holistic approaches are necessary to fully understand the complexities of participation and the potential barriers and facilitators experienced by families. This research has been able to highlight barriers and facilitators of family occupational participation and themes that impact these. Participation is complex with a variety of factors influencing this. The themes of "Just getting on with it", outside support and the impact on mental health were found to be barriers and facilitators to participation. With participation being an important area of childhood development, it is vital for decreased participation to be addressed by health professionals to fully support the continuing care of a child with JIA and their family. <h3>REFERENCES:</h3> <b>NIL.</b> <h3>Acknowledgements:</h3> <b>NIL.</b> <h3>Disclosure of Interests:</h3> <b>None declared.</b>
POS0216 MAPPING IN NORMAL SUBJECTS DIFFERENT BODY AREAS FOR DERMAL THICKNESS AND SKIN HARDNESS BY HIGH FREQUENCY SONOGRAPHY AND DUROMETRY
Authors: M. Cutolo, E. Hysa, N. Berghen, T. Du Four, A. Cere, K. Wyckstandt, E. Gotelli, V. Smith
Journal: Annals of the Rheumatic Diseases (2024)

<h3>Background:</h3> Skin involvement is a prominent feature of systemic sclerosis (SSc). Inter and intra rater reliability of non-invasive tools such as high frequency skin ultrasound (HFSU) and durometry, which can respectively measure the thickness and hardness of the skin, have been attested and further evaluation of their role in SSc is ongoing. However, to date, few data are available in normal subjects. <h3>Objectives:</h3> Our study pilotes a comprehensive skin mapping reporting dermal thickness and skin hardness in healthy individuals using HFUS and durometry to establish preliminary normal distribution values in the same areas already used to evaluate the SSc skin thickness by the modified Rodnan skin score (mRSS). <h3>Methods:</h3> One-hundred-fifty-two healthy volunteers from Ghent (North Europe) and Genoa (South Europe) University Hospitals, divided into three age groups with different ages (mean ages 31.2 ± 9.13, 46.1 ± 15.81, and 64.9 ± 15.1 years with a percentage of females of respectively, 78%, 73% and 64%) were enrolled. No rheumatologic diseases were reported for anyone. HFUS and durometry were used to assess dermal status in the different 17 mRSS areas. Average dermal thickness was reported in mm. Hardness assessed by durometry was expressed in durometer units (DU). <h3>Results:</h3> The mean dermal thickness of Ghent/Genoa's (3 groups) and the mean dermal hardness for the first Ghent's cohort are displayed in Table 1. The upper and lower arms exhibited significantly higher durometry values and lower dermal thickness compared to the trunk regions, underscoring distinct variations across these body areas (p-values &lt; 0.05). Significant differences in dermal thickness were reported for each area assessed among the three groups, apparently related to geographical/ethnical variations and mainly to different age and sex ratio (lowest values in older age and with less women group, see Table 1). <h3>Conclusion:</h3> The study offers the first comprehensive mapping skin status in healthy individuals obtained from two different centers. The numerical mapped values may be used as normal reference values when quantifying by HFUS the specific skin body status in fibrotic skin like in SSc patients. The role of aging and gender effects on skin thickness will be evaluated in external validation studies in the future. <h3>REFERENCES:</h3> <b>NIL.</b> <h3>Acknowledgements:</h3> Maurizio Cutolo and Elvis Hysa share the first authorship of the abstract. <h3>Disclosure of Interests:</h3> <b>None declared.</b>
POS0257 MOLECULAR CLASSIFICATION OF SALIVARY GLANDS IN PRIMARY SJOGREN’S SYNDROME
Authors: H. Xu, X. Wang, L. Jing, S. Ying, J. Hong, H. Cheng, P. Wang, Y. He, J. Zhang, W. Ye, X. Zhu, C. Zhu, L. Yang, Z. LI, S. Lin, D. Chen, X. Wu, Z. Xie, J. Wu
Journal: Annals of the Rheumatic Diseases (2024)

<h3>Background:</h3> Primary Sjögren's syndrome (pSS) is a heterogeneous systemic autoimmune disease marked with varied clinical manifestations and diversified treatment response, potentially due to different pathogeneses among patients. <h3>Objectives:</h3> Our study aimed to clarify the etiology and molecular variation of the target organ, salivary glands (SGs), in pSS by stratifying them into distinguishable subgroups, which could inform treatment choices in pSS. <h3>Methods:</h3> Large-scale transcriptomic profiling of SGs was conducted on 396 pSS, 87 non-pSS, and 44 early-pSS individuals from a multicenter consecutive Chinese cohort. Unsupervised clustering methods were used for molecular classification and integrated analyses were performed to elucidate comprehensive clinical and biological features, immune-metabolic and genetic characteristics. Lymphoma risk and treatment response for pSS subgroups was also predicted for pSS subtypes. <h3>Results:</h3> In this study, we identified the following three molecular subtypes: Quiescent Immune (QI), Mitochondrial Stress Immune (MSI) and Oxidative-Phosphorylation Active Immune (OPAI). The QI subtype exhibited the lowest inflammatory and immune features among the three patient groups and had a gene expression pattern close to non-pSS. Both MSI and OPAI subtypes had significant infiltration of lymphocytes and activation of immune-related pathways. MSI subtype additionally showed prominent structural damage and dysfunction of mitochondria, which resulted in downregulation of ATP-dependent pathways, and activation of cGAS-STING signaling. However, OPAI subtype was marked with active mitochondrial oxidative phosphorylation (OXPHOS), upregulation in metabolism associated pathways and a distinct alternative splicing profile with fewer but specifically oxidative phosphorylation-associated differential alternative splicing events. In addition, we developed random forest models to discriminate these subtypes based on molecular features for potential clinical translation. <h3>Conclusion:</h3> Overall, our findings provide a comprehensive and in-depth molecular landscape of SGs in pSS, shedding light on the disease heterogeneity and promoting the development of precise clinical intervention strategies for pSS patients. <h3>REFERENCES:</h3> <b>NIL.</b> <b>Note:</b> GC, germinal center; OSS, ocular staining score; ANA, antinuclear antibodies; IgG, immunoglobulin G, Hyper-IgG means IgG &gt; 16g/L; ESR, erythrocyte sedimentation rate, Hyper-ESR means ESR&gt; 20mm/H; ESSDAI, EULAR Sjogren's Syndrome Disease Activity Index; sd, standard deviation; QI, Quiescent Immune; MSI, Mitochondrial Stress Immune; OPAI, Oxidative-Phosphorylation Active Immune; *, <i>p</i>&lt;0.05; **, <i>p</i>&lt;0.01; ***, <i>p</i>&lt;0.001. <h3>Acknowledgements:</h3> <b>NIL.</b> <h3>Disclosure of Interests:</h3> <b>None declared.</b>
POS1001 INDUCED PLURIPOTENT STEM CELL-DERIVED MESENCHYMAL STEM CELLS ALLEVIATE SJÖGREN’S SYNDROME BY MODULATING THE MATURATION PROCESS OF SPLENIC B CELLS
Authors: X. Liang, Y. LI, D. Huang, Y. Wu, T. Wu, R. Liao, Y. Liu
Journal: Annals of the Rheumatic Diseases (2024)

<h3>Background:</h3> Sjogren's Syndrome (SS) is a chronic systemic autoimmune disease characterized by the development of lymphocyte infiltration lesions in salivary and lacrimal glands, leading to disruption of their secretory function. This results in clinical manifestations such as xerostomia and dry eye, significantly impacting patients' quality of life. Unfortunately, effective treatment options for this condition are extremely limited. Mesenchymal stem cells (MSCs) and their derivatives hold great promise as potential therapeutic strategies for SS due to their remarkable immunoregulatory capacity. However, the underlying mechanisms responsible for these beneficial effects remain poorly understood. <h3>Objectives:</h3> Therefore, the objective of this study is to elucidate the specific mechanism through which induced pluripotent stem cell-derived MSCs (iMSCs) therapy can effectively regulate immunoregulation in the treatment of SS. <h3>Methods:</h3> MSCs were administered intravenously via the tail vein into NOD/ShiLtJ mice, a spontaneous SS model. The salivary flow rate (SFR) was quantified, while lymphatic infiltration in the submandibular gland was assessed using HE staining. Additionally, immunofluorescence staining was employed to evaluate T cell and B cell infiltration in the submandibular gland, whereas flow cytometry was utilized to detect T cells and B cells in the spleen. <h3>Results:</h3> Compared to the ICR mice, the NOD/ShiLtJ mice exhibited a decrease in SFR, which was subsequently recovered after iMSC treatment. Histological examination using HE staining revealed the absence of lymphocyte infiltration foci in the ICR mice, extensive lymphocyte infiltration foci in the NOD/ShiLtJ mice, and reduced lymphocyte infiltration following iMSC treatment. Analysis of the number and area ratio of lymphocyte infiltration foci indicated that iMSCs inhibited their formation. Furthermore, immunofluorescence staining for CD19 and CD3 in submandibular glands revealed a significant decrease in both T cells (CD3-positive cells) and B cells (CD19-positive cells) following iMSC treatment. Moreover, flow cytometry analysis of mouse spleen demonstrated an aberrant expansion of marginal zone B cells (MZB, B220+CD21hiCD23lo), which are mature B cells, as well as a down-regulation of transitional B cells (TRB, B220+CD21-CD23-) in NOD/ShiLtJ mice. Treatment with iMSCs resulted in a reduced proportion of MZB cells and an increased proportion of TRB cells. <h3>Conclusion:</h3> Our fundings support the notion that iMSCs exhibit a protective effect against SS by inhibiting the maturation of B cells, thereby establishing a theoretical basis for comprehending the role of iMSCs in SS. <h3>REFERENCES:</h3> <b>NIL.</b> <h3>Acknowledgements:</h3> <b>NIL.</b> <h3>Disclosure of Interests:</h3> <b>None declared.</b>